Human immunodeficiency virus-related microbial translocation and progression of hepatitis C - PubMed (original) (raw)
Human immunodeficiency virus-related microbial translocation and progression of hepatitis C
Ashwin Balagopal et al. Gastroenterology. 2008 Jul.
Abstract
Background & aims: Human immunodeficiency virus (HIV)-1 infection has been associated with enhanced microbial translocation, and microbial translocation is a mechanism through which alcohol and some enteric conditions cause liver disease. We hypothesized that HIV promotes liver disease by enhancing microbial translocation.
Methods: We studied human cohorts in which hepatitis C virus (HCV) and HIV outcomes were carefully characterized.
Results: HIV-related CD4(+) lymphocyte depletion was strongly associated with microbial translocation as indicated by elevated levels of circulating lipopolysaccharide (LPS), LPS-binding protein, soluble CD14, and fucose-binding lectin (AAL) reactive to immunoglobulin G specific for the alpha-galactose epitope and suppressed levels of endotoxin core antibodies (EndoCAb IgM) in HIV-infected subjects compared with the same persons before they had HIV infection and compared with HIV-uninfected subjects. The same measures of microbial translocation were strongly associated with HCV-related liver disease progression (cirrhosis), eg, LPS, odds ratio, 19.0 (P = .002); AAL, odds ratio, 27.8 (P < .0001); in addition, levels of LPS were elevated prior to recognition of cirrhosis.
Conclusions: Microbial translocation may be a fundamental mechanism through which HIV accelerates progression of chronic liver disease.
Conflict of interest statement
The authors have no financial conflicts of interest to report.
Figures
Figure 1a–e
Increased microbial translocation and immune activation in HIV-infected subjects with stratified CD4+ lymphocyte counts compared to those without HIV infection. a. LPS, b. LBP, c. sCD14, d. AAL, and e. EndoCAb IgM was compared in 17 subjects with liver disease and 71 subjects without in the presence and absence of HIV infection. Each marker was measured in stored serum samples. Each point represents the value from one subject’s serum. P-values were generated by Wilcoxon Rank-Sum test procedure, and *p<0.05 was considered to be significant.
Figure 1a–e
Increased microbial translocation and immune activation in HIV-infected subjects with stratified CD4+ lymphocyte counts compared to those without HIV infection. a. LPS, b. LBP, c. sCD14, d. AAL, and e. EndoCAb IgM was compared in 17 subjects with liver disease and 71 subjects without in the presence and absence of HIV infection. Each marker was measured in stored serum samples. Each point represents the value from one subject’s serum. P-values were generated by Wilcoxon Rank-Sum test procedure, and *p<0.05 was considered to be significant.
Figure 1a–e
Increased microbial translocation and immune activation in HIV-infected subjects with stratified CD4+ lymphocyte counts compared to those without HIV infection. a. LPS, b. LBP, c. sCD14, d. AAL, and e. EndoCAb IgM was compared in 17 subjects with liver disease and 71 subjects without in the presence and absence of HIV infection. Each marker was measured in stored serum samples. Each point represents the value from one subject’s serum. P-values were generated by Wilcoxon Rank-Sum test procedure, and *p<0.05 was considered to be significant.
Figure 1a–e
Increased microbial translocation and immune activation in HIV-infected subjects with stratified CD4+ lymphocyte counts compared to those without HIV infection. a. LPS, b. LBP, c. sCD14, d. AAL, and e. EndoCAb IgM was compared in 17 subjects with liver disease and 71 subjects without in the presence and absence of HIV infection. Each marker was measured in stored serum samples. Each point represents the value from one subject’s serum. P-values were generated by Wilcoxon Rank-Sum test procedure, and *p<0.05 was considered to be significant.
Figure 1a–e
Increased microbial translocation and immune activation in HIV-infected subjects with stratified CD4+ lymphocyte counts compared to those without HIV infection. a. LPS, b. LBP, c. sCD14, d. AAL, and e. EndoCAb IgM was compared in 17 subjects with liver disease and 71 subjects without in the presence and absence of HIV infection. Each marker was measured in stored serum samples. Each point represents the value from one subject’s serum. P-values were generated by Wilcoxon Rank-Sum test procedure, and *p<0.05 was considered to be significant.
Figure 2
HCV seroconversion is not significantly associated with microbial translocation. Thirty-four persons had levels of microbial translocation markers drawn before and after acute HCV seroconversion. LPS levels were not different after seroconversion, as shown. Similar results were found for other microbial translocation markers.
Figure 3
HIV-related intestinal CD4+ lymphocyte depletion and microbial translocation contribute to HCV progression. An integrated model shows that microbial translocation is dependent on HIV-related CD4+ lymphocyte depletion. Microbial translocation is critical for the development of immune activation and AIDS, but liver disease develops only in HCV co-infection. Microbial translocation in the host with cirrhosis will lead to less clearance of bacterial products, and increased immune activation.
Similar articles
- Microbial translocation and liver disease progression in women coinfected with HIV and hepatitis C virus.
French AL, Evans CT, Agniel DM, Cohen MH, Peters M, Landay AL, Desai SN. French AL, et al. J Infect Dis. 2013 Aug 15;208(4):679-89. doi: 10.1093/infdis/jit225. Epub 2013 May 17. J Infect Dis. 2013. PMID: 23687224 Free PMC article. - Host response to translocated microbial products predicts outcomes of patients with HBV or HCV infection.
Sandler NG, Koh C, Roque A, Eccleston JL, Siegel RB, Demino M, Kleiner DE, Deeks SG, Liang TJ, Heller T, Douek DC. Sandler NG, et al. Gastroenterology. 2011 Oct;141(4):1220-30, 1230.e1-3. doi: 10.1053/j.gastro.2011.06.063. Epub 2011 Jul 2. Gastroenterology. 2011. PMID: 21726511 Free PMC article. - Liver fibrosis, microbial translocation and immune activation markers in HIV and HCV infections and in HIV/HCV co-infection.
Sacchi P, Cima S, Corbella M, Comolli G, Chiesa A, Baldanti F, Klersy C, Novati S, Mulatto P, Mariconti M, Bazzocchi C, Puoti M, Pagani L, Filice G, Bruno R. Sacchi P, et al. Dig Liver Dis. 2015 Mar;47(3):218-25. doi: 10.1016/j.dld.2014.11.012. Epub 2014 Nov 29. Dig Liver Dis. 2015. PMID: 25544657 - HIV and hepatitis C coinfection: pathogenesis and microbial translocation.
Page EE, Nelson M, Kelleher P. Page EE, et al. Curr Opin HIV AIDS. 2011 Nov;6(6):472-7. doi: 10.1097/COH.0b013e32834bbc71. Curr Opin HIV AIDS. 2011. PMID: 21918438 Review. - Circulating LPS and (1→3)-β-D-Glucan: A Folie à Deux Contributing to HIV-Associated Immune Activation.
Ramendra R, Isnard S, Mehraj V, Chen J, Zhang Y, Finkelman M, Routy JP. Ramendra R, et al. Front Immunol. 2019 Mar 18;10:465. doi: 10.3389/fimmu.2019.00465. eCollection 2019. Front Immunol. 2019. PMID: 30967860 Free PMC article. Review.
Cited by
- Microbiota, natural products, and human health: exploring interactions for therapeutic insights.
Qadri H, Shah AH, Almilaibary A, Mir MA. Qadri H, et al. Front Cell Infect Microbiol. 2024 Jul 5;14:1371312. doi: 10.3389/fcimb.2024.1371312. eCollection 2024. Front Cell Infect Microbiol. 2024. PMID: 39035357 Free PMC article. Review. - A gut microbiome signature for HIV and metabolic dysfunction-associated steatotic liver disease.
Martínez-Sanz J, Talavera-Rodríguez A, Díaz-Álvarez J, Rosas Cancio-Suárez M, Rodríguez JM, Alba C, Montes ML, Martín-Mateos R, Burgos-Santamaría D, Moreno S, Serrano-Villar S, Sánchez-Conde M. Martínez-Sanz J, et al. Front Immunol. 2023 Dec 14;14:1297378. doi: 10.3389/fimmu.2023.1297378. eCollection 2023. Front Immunol. 2023. PMID: 38162648 Free PMC article. - Endotoxemia Associated with Liver Disease Correlates with Systemic Inflammation and T Cell Exhaustion in Hepatitis C Virus Infection.
Shive CL, Kowal CM, Desotelle AF, Nguyen Y, Carbone S, Kostadinova L, Davitkov P, O'Mara M, Reihs A, Siddiqui H, Wilson BM, Anthony DD. Shive CL, et al. Cells. 2023 Aug 10;12(16):2034. doi: 10.3390/cells12162034. Cells. 2023. PMID: 37626844 Free PMC article. - The human microbiome and gut-liver axis in people living with HIV.
Duarte MJ, Tien PC, Somsouk M, Price JC. Duarte MJ, et al. Curr HIV/AIDS Rep. 2023 Jun;20(3):170-180. doi: 10.1007/s11904-023-00657-x. Epub 2023 May 2. Curr HIV/AIDS Rep. 2023. PMID: 37129834 Free PMC article. Review. - Nutritional and Lifestyle Therapy for NAFLD in People with HIV.
Cinque F, Cespiati A, Lombardi R, Guaraldi G, Sebastiani G. Cinque F, et al. Nutrients. 2023 Apr 20;15(8):1990. doi: 10.3390/nu15081990. Nutrients. 2023. PMID: 37111209 Free PMC article. Review.
References
- Weber R, Sabin CA, Friis-Moller N, et al. Liver-related deaths in persons infected with the human immunodeficiency virus: the D:A:D study. Arch Intern Med. 2006;166:1632–1641. - PubMed
- Goedert JJ, Eyster ME, Lederman MM, et al. End-stage liver disease in persons with hemophilia and transfusion- associated infections. Blood. 2002;100:1584–1589. - PubMed
- Thio CL, Seaberg EC, Skolasky RL, et al. HIV-1, hepatitis B virus, and risk of liver-related mortality in the Multicenter AIDS Cohort Study (MACS) Lancet. 2002;360:1921–1926. - PubMed
- Smit-McBride Z, Mattapallil JJ, McChesney M, et al. Gastrointestinal T lymphocytes retain high potential for cytokine responses but have severe CD4(+) T-cell depletion at all stages of simian immunodeficiency virus infection compared to peripheral lymphocytes. J Virol. 1998;72:6646–6656. - PMC - PubMed
- Veazey RS, DeMaria M, Chalifoux LV, et al. Gastrointestinal tract as a major site of CD4+ T cell depletion and viral replication in SIV infection. Science. 1998;280:427–431. - PubMed
Publication types
MeSH terms
Grants and funding
- U01 DA036935/DA/NIDA NIH HHS/United States
- R01 2 DA012568/DA/NIDA NIH HHS/United States
- R01 CA120206-02/CA/NCI NIH HHS/United States
- K08 AI081544/AI/NIAID NIH HHS/United States
- R01 DA012568-10/DA/NIDA NIH HHS/United States
- R37 DA004334-20/DA/NIDA NIH HHS/United States
- R01 DA012568/DA/NIDA NIH HHS/United States
- U01 CA084951-09/CA/NCI NIH HHS/United States
- R01 DA013806-08/DA/NIDA NIH HHS/United States
- T32 AI07291/AI/NIAID NIH HHS/United States
- R01 AA016893/AA/NIAAA NIH HHS/United States
- U01 CA084951/CA/NCI NIH HHS/United States
- R01 DA011602-10/DA/NIDA NIH HHS/United States
- U01CA084951/CA/NCI NIH HHS/United States
- R37 DA004334/DA/NIDA NIH HHS/United States
- R01 DA011602/DA/NIDA NIH HHS/United States
- T32 AI007291/AI/NIAID NIH HHS/United States
- R56 DA004334/DA/NIDA NIH HHS/United States
- R01CA120206/CA/NCI NIH HHS/United States
- R01 DA016078-06/DA/NIDA NIH HHS/United States
- R01 DA016078/DA/NIDA NIH HHS/United States
- R01 CA120206/CA/NCI NIH HHS/United States
- 1 R37DA004334/DA/NIDA NIH HHS/United States
- R01 DA013806/DA/NIDA NIH HHS/United States
LinkOut - more resources
Full Text Sources
Medical
Research Materials